Results 1 to 10 of about 2,249 (191)

Lebrikizumab in the personalized management of asthma

Biologics: Targets and Therapy, 2012
Neil C Thomson,1 Manish Patel,2 Andrew D Smith21Institute of Infection, Immunity, and Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK; 2Department of Respiratory Medicine, Wishaw Hospital, Wishaw ...
Neil C Thomson, Manish Patel, A D Smith
exaly   +8 more sources

Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison [PDF]

Dermatology and Therapy
Introduction A matching-adjusted indirect comparison evaluated the short-term efficacy of lebrikizumab plus topical corticosteroids (TCS) versus dupilumab plus TCS in adults with moderate-to-severe atopic dermatitis (AD).
Raj Chovatiya, April Armstrong, Leon Kircik, Lluís Puig, Mark G. Kirchhof, Tiago Torres, Yousef Binamer, Gleison Duarte, Bülent Akmaz, Martin Dossenbach, Gaia Gallo, Chao Yang, Lucia Seminario-Vidal, Yuxin Ding, Jonathan I. Silverberg   +14 more
doaj   +2 more sources

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials.
Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold   +2 more
exaly   +2 more sources

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol [PDF]

BMJ Open
Introduction Atopic dermatitis (AD) is a chronic, relapsing, heterogeneous skin disease affecting 2%–7% of adults, with roughly 30% having moderate-to-severe disease.
Matthias Augustin, Hilde Lapeere, Anthony Bewley, Christian Vestergaard, Thomas Werfel, Eric Massana, Ismail Kasujee, Marie-Charlotte Brüggen, Marjolein S de Bruin-Weller, Khaled Ezzedine, Silvia M Ferrucci, Spyridon Gkalpakiotis, Pedro Herranz, Emma K Johansson, Tomáš Kampe, Franz J Legat, Eva Maria Rehbinder, Jacek C Szepietowski, Tiago Torres, Arnau Domenech, Volker Koscielny, Siva Narayanan, Jan Gutermuth   +22 more
doaj   +2 more sources

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that selectively binds to interleukin (IL)-13 with high affinity and a slow dissociation rate.
Emma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, Nathan Hahn, Brian J. Nickoloff, Christoph Preuss, Kimberly Siu, Chitra R. Natalie, Gaia Gallo, Eric Wolf, Kilian Eyerich, Mònica Aparici, Robert J. Benschop, Angela Okragly   +13 more
doaj   +2 more sources

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy [PDF]

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +2 more sources

Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies [PDF]

Antibodies
Background: Head and neck dermatitis (HND) represents a challenging phenotype of atopic dermatitis (AD), often showing suboptimal response or paradoxical worsening during biologic therapy.
Giuseppe Lauletta, Cataldo Patruno, Claudio Brescia, Andrea Cosenza, Carolina D’Elia, Valentina Ventura, Emanuela Martina, Maddalena Napolitano   +7 more
doaj   +2 more sources

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Journal of Dermatological Treatment
Background Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe ...
Carsten Flohr
exaly   +3 more sources

Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials.
Gianluca Avallone, Andrea Bombelli, Luigi Gargiulo, Caterina Foti, Ilaria Trave, Mariateresa Rossi, Elisabetta Magnaterra, Flavia Pigliacelli, Piergiorgio Malagoli, Serena Giacalone, Antonio Portarapillo, Cataldo Patruno, Natale Schettini, Laura Bonzano, Elena Pezzolo, Camilla Chello, Niccolò Gori, Giovanna Brunasso, Federica Veronese, Michela Ortoncelli, Ersilia Tolino, Alan Azzolini, Francesco Bellinato, Katharina Hansel, Eugenia Veronica Di Brizzi, Carlotta Gurioli, Maria Esposito, Roberta Giuffrida, Francesca Barei, Paolo Calzari, Anna Graziella Burroni, Massimo Gola, Maria Mariano, Maria Concetta Fargnoli, Maddalena Napolitano, Teresa Grieco, Ketty Peris, Paola Savoia, Simone Ribero, Giampiero Girolomoni, Luca Stingeni, Anna Balato, Antonio Costanzo, Angelo Valerio Marzano, Alessandra Narcisi, Silvia Mariel Ferrucci   +45 more
doaj   +2 more sources

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient’s quality of life (QoL) and mental health.
Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres   +12 more
doaj   +2 more sources